🏛️ Verified NIH Record • Updated 2025-02-06
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (NCT05032040)
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Xencor, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
- UCSD Moores Cancer Center — La Jolla, California
- Valkyrie Clinical Trials — Los Angeles, California
- UCLA Medical Center — Los Angeles, California
- Kaiser Permanente Medical Group — Riverside, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
- Medical Oncology Hematology Consultants, PA — Newark, Delaware
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Karmanos Cancer Institute — Detroit, Michigan
- Comprehensive Cancer Centers of Nevada-Southern Hills — Las Vegas, Nevada
- NYU Langone Health — New York, New York
- Columbia University Medical Center — New York, New York
- University of Pennsylvania Health System — Philadelphia, Pennsylvania
- Texas Oncology - Central South — Austin, Texas
- Virginia Oncology Associates — Norfolk, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.